Understanding Payer Decision-Making: TRANSPERS Program on Coverage and Reimbursement

Insurance coverage is critical for sustained implementation of precision medicine into clinical practice. How payers decide on coverage informs research, evidence generation, and clinical adoption of new genomic technologies. This is especially relevant in a multi-payer health care system, such as in the U.S., where inconsistency of decision-making across payers contributes to variable insurance coverage and unequal access to new genomic technologies.

There is a **gap in understanding** what factors and considerations impact payers’ decision-making, what evidence is needed, and how these factors vary across payers and testing modalities. Additionally, there is a **lack of forums** to explore payer decision-making objectively. While companies engage payers in advisory boards, these boards tend to serve commercial interests, rather than independent research.

To address this, we assembled the **UCSF TRANSPERS Payer Advisory Board** in 2007. Since then, we have conducted a unique research program in collaboration with the Board.

Board members represent **key stakeholders**, including:
- Leading national and regional private insurer plans
- Business groups representing large, self-insured employers
- Laboratory benefit management companies
- Experts in public payer policies

Our research program is conducted using **two methods**:
- Individual interview studies with Board members on their perspectives relevant to coverage decision-making for emerging technologies and tests
- Board roundtables featuring group discussions

**Accomplishments**

Since the founding of the Board, our research has resulted in numerous peer-reviewed publications in major journals, as well as reports. Our work has been widely cited and used by researchers, payers, industry, organizations, and venture capital firms. Our 2020 paper in Genetics in Medicine on perspectives of U.S. private payers on insurance coverage for pediatric and prenatal exome sequencing was among their top 15% articles cited that year.

For more information: [https://pharm.ucsf.edu/transpers/grants-programs/evidence-reimbursement](https://pharm.ucsf.edu/transpers/grants-programs/evidence-reimbursement)